{"id":998117,"date":"2026-08-26T07:33:41","date_gmt":"2026-08-26T11:33:41","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/eikon-therapeutics-to-participate-in-investor-conferences-in-september-2026\/"},"modified":"2026-08-26T07:33:41","modified_gmt":"2026-08-26T11:33:41","slug":"eikon-therapeutics-to-participate-in-investor-conferences-in-september-2026","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/eikon-therapeutics-to-participate-in-investor-conferences-in-september-2026\/","title":{"rendered":"Eikon Therapeutics to Participate in Investor Conferences in September 2026"},"content":{"rendered":"<div class=\"mw_release\">\n<p>MILLBRAE, Calif., Aug.  26, 2026  (GLOBE NEWSWIRE) &#8212; Eikon Therapeutics, Inc. (Nasdaq: EIKN) (\u201cEikon\u201d), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced that Roger M. Perlmutter, M.D., Ph.D., Chairman and Chief Executive Officer, and Freddie Bowie, Ph.D., Chief Financial Officer, will participate in two upcoming investor conferences taking place in September:<\/p>\n<p>\n        <strong>Event<\/strong>:<em>12<\/em><sup><em>th<\/em><\/sup><em> Annual Cantor Global Healthcare Conference<\/em><br \/><strong>Location<\/strong>: New York, NY<br \/><strong>Date &amp; Time<\/strong>: September 10, 2026 at 2:10 pm ET<br \/><strong>Format<\/strong>: Fireside Chat<\/p>\n<p>\n        <strong>Event<\/strong>: The Morgan Stanley 24th Annual Global Healthcare Conference<br \/><strong>Location<\/strong>: New York, NY<br \/><strong>Date &amp; Time<\/strong>: September 15, 2026 at 4:05 pm ET<br \/><strong>Format<\/strong>: Fireside Chat<\/p>\n<p>Live audio\/video webcasts of these presentations will be accessible through Eikon\u2019s investor relations website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=gsdsEkpleMsJC9ApvYgqYZe5UTWWF5Edo8lsTcaI1LaJKERBCw6a4d841N0LhFdQlxsz5_TEVGlTNLP5itH8F9gd0Aj2-iM-cz34oQ9tGaBsahyzoinYn0H7mQHmdqlp\" rel=\"nofollow\" target=\"_blank\">www.investors.eikontx.com<\/a>, with an archived edition of the session available later that day and accessible for approximately 30 days after the live event.<\/p>\n<p>\n        <strong>About Eikon Therapeutics<\/strong><br \/>\n        <br \/>Eikon is a late-stage clinical biopharmaceutical company dedicated to building a global, fully-integrated organization developing innovative medicines to address serious unmet medical needs. Eikon\u2019s initial focus is oncology, where it is advancing a pipeline of drug candidates targeting areas of high unmet need that could eventually become critical medicines for the treatment of various cancers. Eikon deploys its technology platform, including its proprietary single molecule tracking system, to develop internally-derived novel therapies, while also leveraging the deep expertise of its management team to in-license promising assets. Eikon\u2019s vision is to become a generational leader, by purposefully integrating traditional biology research with advanced engineering to develop better medicines faster. For more information, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=9Rvm60z3M9iQpUWWhHM4YwJwhpqCfXB6DQpjsuiBkfqYNFsPgBLvMoLfmZkwXpY23r4D6yhSy7nNqYrb0LrOAZwTc5STNGsFAMLHgZ36mEA=\" rel=\"nofollow\" target=\"_blank\">www.eikontx.com<\/a>.<\/p>\n<p>\n        <strong>Forward-Looking\/Safe Harbor Statements<\/strong><br \/>\n        <br \/>This press release contains forward-looking statements within the meaning of the \u201csafe harbor\u201d provisions of the Private Securities Litigation Reform Act of 1995. All statements in this press release that are not historical facts are hereby identified as forward-looking statements for this purpose. These statements may be identified by words such as \u201caims,\u201d \u201canticipates,\u201d \u201cbelieves,\u201d \u201ccould,\u201d \u201cestimates,\u201d \u201cexpects,\u201d \u201cforecasts,\u201d \u201cgoal,\u201d \u201cintends,\u201d \u201cmay,\u201d \u201cplans,\u201d \u201cpossible,\u201d \u201cpotential,\u201d \u201cseeks,\u201d \u201cwill\u201d and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, but are not limited to, statements regarding: the therapeutic potential, safety, and efficacy of Eikon\u2019s product candidates; the timing for anticipated data readouts; expected milestones and business objectives for 2026 and beyond; and other statements regarding Eikon\u2019s future operations, financial performance, financial position, prospects, objectives, strategies and other future events.<\/p>\n<p>These forward-looking statements are based upon management\u2019s current expectations and assumptions, and are subject to a number of risks, uncertainties and other factors that could cause actual results and events to differ materially and adversely from those indicated by such forward-looking statements including, among others: our limited operating history; our significant net losses incurred since inception and the likelihood of incurring additional losses for the foreseeable future; our need for substantial additional funding; the early stage of development of many of our product candidates and the possibility that our product candidates may fail in development; our dependence on the success of our current product candidates; our ability to leverage our technology platform to enable more informed drug research and development; legal and regulatory risks; intellectual property-related risks; and those risks, uncertainties and other factors discussed under the caption \u201cRisk Factors\u201d and elsewhere in Eikon\u2019s Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, filed with the Securities and Exchange Commission (\u201cSEC\u201d) on August 13, 2026, and in other public filings with the SEC in the future.<\/p>\n<p>As a result, you should not place undue reliance on any forward-looking statements. The forward-looking statements made in this press release speak only as of the date of this press release, and Eikon undertakes no obligation to update such forward-looking statements, whether as a result of new information, future developments or otherwise, except as required by law.<\/p>\n<p>\n        <strong>Contacts:<\/strong>\n      <\/p>\n<p>\n        <strong>Investors<\/strong><br \/>\n        <br \/>Alfred \u201cFreddie\u201d Bowie, Ph.D., CFO<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=R3N_sT1NEO1TrCCU7SOo_kfuAhzy1WMYUmKWvUam25aBdYuMaunrSLQN1i0r3htjn7qKfYEnROZjWUq64K7iMA==\" rel=\"nofollow\" target=\"_blank\">ir@eikontx.com<\/a><\/p>\n<p>\n        <strong>Media<\/strong><br \/>\n        <br \/>Colin Sanford<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=dptfGBbz0HrC9QqbNnL8H2MoztltLBB7Boo2B_OxOpZ8vKRgm3CDSzqFJXPvWDPh7fyYSV4W7cxVXM2oVmFl6SMZFK_80z0OeLZVHqS74ZU=\" rel=\"nofollow\" target=\"_blank\">colin@bioscribe.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgxNjI2MiM3ODAzNjM5IzIzMDgwOTM=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/ODZjMGMxY2ItMDE3ZC00MzIyLWEwNzUtYjI3MTJkNjhjYTY1LTEzMTk2NDMtMjAyNi0wOC0yNi1lbg==\/tiny\/Eikon-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>MILLBRAE, Calif., Aug. 26, 2026 (GLOBE NEWSWIRE) &#8212; Eikon Therapeutics, Inc. (Nasdaq: EIKN) (\u201cEikon\u201d), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced that Roger M. Perlmutter, M.D., Ph.D., Chairman and Chief Executive Officer, and Freddie Bowie, Ph.D., Chief Financial Officer, will participate in two upcoming investor conferences taking place in September: Event:12th Annual Cantor Global Healthcare ConferenceLocation: New York, NYDate &amp; Time: September 10, 2026 at 2:10 pm ETFormat: Fireside Chat Event: The Morgan Stanley 24th Annual Global Healthcare ConferenceLocation: New York, NYDate &amp; Time: September 15, 2026 at 4:05 pm ETFormat: Fireside Chat Live audio\/video webcasts of these presentations will be accessible through Eikon\u2019s investor relations website at www.investors.eikontx.com, &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/eikon-therapeutics-to-participate-in-investor-conferences-in-september-2026\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Eikon Therapeutics to Participate in Investor Conferences in September 2026&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-998117","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Eikon Therapeutics to Participate in Investor Conferences in September 2026 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/eikon-therapeutics-to-participate-in-investor-conferences-in-september-2026\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Eikon Therapeutics to Participate in Investor Conferences in September 2026 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"MILLBRAE, Calif., Aug. 26, 2026 (GLOBE NEWSWIRE) &#8212; Eikon Therapeutics, Inc. (Nasdaq: EIKN) (\u201cEikon\u201d), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced that Roger M. Perlmutter, M.D., Ph.D., Chairman and Chief Executive Officer, and Freddie Bowie, Ph.D., Chief Financial Officer, will participate in two upcoming investor conferences taking place in September: Event:12th Annual Cantor Global Healthcare ConferenceLocation: New York, NYDate &amp; Time: September 10, 2026 at 2:10 pm ETFormat: Fireside Chat Event: The Morgan Stanley 24th Annual Global Healthcare ConferenceLocation: New York, NYDate &amp; Time: September 15, 2026 at 4:05 pm ETFormat: Fireside Chat Live audio\/video webcasts of these presentations will be accessible through Eikon\u2019s investor relations website at www.investors.eikontx.com, &hellip; Continue reading &quot;Eikon Therapeutics to Participate in Investor Conferences in September 2026&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/eikon-therapeutics-to-participate-in-investor-conferences-in-september-2026\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-26T11:33:41+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgxNjI2MiM3ODAzNjM5IzIzMDgwOTM=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eikon-therapeutics-to-participate-in-investor-conferences-in-september-2026\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eikon-therapeutics-to-participate-in-investor-conferences-in-september-2026\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Eikon Therapeutics to Participate in Investor Conferences in September 2026\",\"datePublished\":\"2026-08-26T11:33:41+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eikon-therapeutics-to-participate-in-investor-conferences-in-september-2026\\\/\"},\"wordCount\":678,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eikon-therapeutics-to-participate-in-investor-conferences-in-september-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgxNjI2MiM3ODAzNjM5IzIzMDgwOTM=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eikon-therapeutics-to-participate-in-investor-conferences-in-september-2026\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eikon-therapeutics-to-participate-in-investor-conferences-in-september-2026\\\/\",\"name\":\"Eikon Therapeutics to Participate in Investor Conferences in September 2026 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eikon-therapeutics-to-participate-in-investor-conferences-in-september-2026\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eikon-therapeutics-to-participate-in-investor-conferences-in-september-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgxNjI2MiM3ODAzNjM5IzIzMDgwOTM=\",\"datePublished\":\"2026-08-26T11:33:41+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eikon-therapeutics-to-participate-in-investor-conferences-in-september-2026\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eikon-therapeutics-to-participate-in-investor-conferences-in-september-2026\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eikon-therapeutics-to-participate-in-investor-conferences-in-september-2026\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgxNjI2MiM3ODAzNjM5IzIzMDgwOTM=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgxNjI2MiM3ODAzNjM5IzIzMDgwOTM=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eikon-therapeutics-to-participate-in-investor-conferences-in-september-2026\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Eikon Therapeutics to Participate in Investor Conferences in September 2026\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Eikon Therapeutics to Participate in Investor Conferences in September 2026 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/eikon-therapeutics-to-participate-in-investor-conferences-in-september-2026\/","og_locale":"en_US","og_type":"article","og_title":"Eikon Therapeutics to Participate in Investor Conferences in September 2026 - Market Newsdesk","og_description":"MILLBRAE, Calif., Aug. 26, 2026 (GLOBE NEWSWIRE) &#8212; Eikon Therapeutics, Inc. (Nasdaq: EIKN) (\u201cEikon\u201d), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced that Roger M. Perlmutter, M.D., Ph.D., Chairman and Chief Executive Officer, and Freddie Bowie, Ph.D., Chief Financial Officer, will participate in two upcoming investor conferences taking place in September: Event:12th Annual Cantor Global Healthcare ConferenceLocation: New York, NYDate &amp; Time: September 10, 2026 at 2:10 pm ETFormat: Fireside Chat Event: The Morgan Stanley 24th Annual Global Healthcare ConferenceLocation: New York, NYDate &amp; Time: September 15, 2026 at 4:05 pm ETFormat: Fireside Chat Live audio\/video webcasts of these presentations will be accessible through Eikon\u2019s investor relations website at www.investors.eikontx.com, &hellip; Continue reading \"Eikon Therapeutics to Participate in Investor Conferences in September 2026\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/eikon-therapeutics-to-participate-in-investor-conferences-in-september-2026\/","og_site_name":"Market Newsdesk","article_published_time":"2026-08-26T11:33:41+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgxNjI2MiM3ODAzNjM5IzIzMDgwOTM=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eikon-therapeutics-to-participate-in-investor-conferences-in-september-2026\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eikon-therapeutics-to-participate-in-investor-conferences-in-september-2026\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Eikon Therapeutics to Participate in Investor Conferences in September 2026","datePublished":"2026-08-26T11:33:41+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eikon-therapeutics-to-participate-in-investor-conferences-in-september-2026\/"},"wordCount":678,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eikon-therapeutics-to-participate-in-investor-conferences-in-september-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgxNjI2MiM3ODAzNjM5IzIzMDgwOTM=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eikon-therapeutics-to-participate-in-investor-conferences-in-september-2026\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/eikon-therapeutics-to-participate-in-investor-conferences-in-september-2026\/","name":"Eikon Therapeutics to Participate in Investor Conferences in September 2026 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eikon-therapeutics-to-participate-in-investor-conferences-in-september-2026\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eikon-therapeutics-to-participate-in-investor-conferences-in-september-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgxNjI2MiM3ODAzNjM5IzIzMDgwOTM=","datePublished":"2026-08-26T11:33:41+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eikon-therapeutics-to-participate-in-investor-conferences-in-september-2026\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/eikon-therapeutics-to-participate-in-investor-conferences-in-september-2026\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eikon-therapeutics-to-participate-in-investor-conferences-in-september-2026\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgxNjI2MiM3ODAzNjM5IzIzMDgwOTM=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgxNjI2MiM3ODAzNjM5IzIzMDgwOTM="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eikon-therapeutics-to-participate-in-investor-conferences-in-september-2026\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Eikon Therapeutics to Participate in Investor Conferences in September 2026"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/998117","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=998117"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/998117\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=998117"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=998117"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=998117"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}